HodgeD, BackDJ, GibbonsS, et al.Pharmacokinetics and drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet, 2021; 60(7):835–853; doi: 10.1007/s40262-021-01005-1
3.
Delany-MoretlweS. Performance of HIV RNA screening in the context of long-acting injectable cabotegravir in HPTN 084. n.d. Available from: https://www.natap.org/2025/CROI/croi_56.htm [Last accessed: March21, 2025].
LandovitzRJ, Delany-MoretlweS, FogelJM, et al.; HPTN 083 and 084 Study Teams. Features of HIV infection in long-acting cabotegravir pre-exposure prophylaxis. N Engl J Med, 2024; 391(13):1253–1256; doi: 10.1056/NEJMc2402088
9.
HazraA, LandovitzRJ, MarzinkeMA, et al.Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS, 2023; 37(11):1711–1714; doi: 10.1097/QAD.0000000000003644
10.
ParikhUM, AltamiranoJ, SafaH, et al.Early virologic success on ART following breakthrough infection on CAB-LA PrEP. n.d. Available from: https://www.natap.org/2024/HIVR4P/HIVR4P_23.htm [Last accessed: February18, 2025].
11.
PetersenJ, MonteiroM, DalalS, et al.Reducing false-positive results with fourth-generation HIV testing at a veterans affairs medical center. Fed Pract, 2021; 38(5):232–237; doi: 10.1278/8/fp.0125
12.
CasperSJ, FixML, SpivakAM. A blind spot in HIV diagnosis guidelines? AIDS, 2025; 39(3):334–335; doi: 10.1097/QAD.0000000000004084